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Abstract 
There has been a tremendous recent resurgence of interest in examining chromosomal abnormalities in 
human cancers (particularly solid tumors). This interest has been stimulated by the molecular examination of 
recurring chromosome abnormalities, and the recognition that they may pinpoint the location of growth 
regulatory sequences (e.g. cellular oncogenes). This finding coupled with the clear recognition that specific 
chromosome abnormalities can also have important diagnostic and prognostic implications, have caused this 
avenue of research to expand at a significant rate. The following brief review will summarize the current state 
of knowledge regarding recurring chromosome abnormalities in human malignant melanoma. A discussion 
of chromosome changes in pre-malignant skin lesions, primary melanoma, and metastatic melanoma is 
described. Brief descriptions of the potential clinical utility, and biologic relevance of chromosome ab- 
normalities in this disorder are also discussed. 
Introduction 
Based upon epidemiologic grounds there has been 
a significant increase in the incidence of malignant 
melanoma worldwide [1]. In North America a dou- 
bling of the incidence rate for melanoma has oc- 
curred each decade for the past forty years, and the 
current estimation is that > 1/100 Americans will 
develop melanoma by the year 2000 [1]. These 
alarming statistics coupled with the realization that 
three fourths of all deaths from skin cancer result 
from melanoma strongly suggests that significant 
attention should be focused on understanding not 
just the clinical behavior, but also the biology and 
genetics of this disorder. In this brief review, em- 
phasis will be exclusively placed upon a discussion 
of the current state of knowledge of chromosomal 
alterations in this important neoplasm. However, 
the underlying viewpoint is that a proportion of 
these chromosomal changes will in fact represent 
byproducts of molecular events which themselves 
may play a causative role in melanoma carcinoge- 
nesis. 
General overview 
Cytogenetic examination of human cancers has sig- 
nificantly expanded over the past decade with more 
than 14,000 cases now reported in the world litera- 
ture [2]. However, our knowledge base is weighted 
heavily toward human hematopoetic malignancies, 
with fewer than 20% of studies focusing on human 
solid tumors (which represent 80% of the cancers 
of man) [2, 3]. Nevertheless, the identification of 
recurring sites of chromosome change in human 
solid tumors (including melanoma) is increasing at 
a tremendous rate. The following sections will 
briefly discuss chromosomal alterations in malig- 
nant melanoma. A brief discussion of chromosome 
alterations in premalignant nevi and early stage 
melanomas will be presented first, followed by a 
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discussion of chromosomal changes occurring in 
metastatic disease. Finally discussion of very pre- 
liminary work suggesting that chromosomal ab- 
normalities may correlate with clinical outcome in 
malignant melanoma, as well as studies related to 
the biologic significance of chromosome abnormal- 
ities will be presented. 
Cytogenetic analysis of premalignant nevi and 
primary melanoma 
The recognition of recurring sites of chromosome 
change has pinpointed several genes involved in 
cellular transformation. Accordingly, an examin- 
ation of the earliest stages of tumor development, 
or the study of premalignant precursor lesions may 
provide significant information of biologic rele- 
vance. Unfortunately, there have been few reports 
on the cytogenetics of early malanocytic lesions, 
either common nevi, dysplastic nevi, or early (radi- 
al growth phase) primary melanomas. The studies 
undertaken to date have focused on two different 
approaches, first analyzing the constitutional ka- 
ryotypes of patients with dysplastic nevus syn- 
drome (DNS) [4, 5], or familial atypical multiple- 
mole melanoma (FAMMM) [6]. Second, cytoge- 
netic examination of melanocytes from dysplastic 
nevi and primary melanoma. 
Cytogenetic studies of peripheral blood lympho- 
cytes from DNS or FAMMM patients have been 
undertaken because both represent inherited dis- 
orders characterized by the occurrence of multiple 
atypical moles and a strongly increased risk for 
melanoma. The mode of inheritance appears to be 
autosomal dominate for both disorders, although 
there is a considerable degree of non-penetrance. 
Chromosome analyses on both DNS and FAMMM 
patient populations have suggested either normal 
karotypes with normal spontaneous sister chroma- 
rid exchange rates in fibroblasts from these individ- 
uals, or slightly enhanced numbers of nonclonal 
cytogenetic abnormalities in affected versus con- 
trol patients [4, 5, 7]. Specifically, some studies 
have shown a statistically significant increase in 
major structural abnormalities in the peripheral 
blood lymphocytes of melanoma patients, while 
numeric abnormalities (again non-clonal and ran- 
dom) are observed more frequently in patients with 
DNS. Unfortunately, because no clonal cytogenet- 
ic abnormalities have yet been observed in any 
family with a hereditary disorder predisposing the 
melanoma, the results of generalized chromosome 
instability are difficult to interpret. Nevertheless, 
there does appear to be some slight increase in the 
level of spontaneous structural and numeric chro- 
mosome abnormalities in patients predisposed to 
the development of malignant melanoma. 
In contrast to the cytogenetic study of peripheral 
blood from a reasonably large number of melan- 
oma prone families, relatively few studies have 
focused on cytogenetic analysis of melanocytes 
from premalignant nevi and primary melanomas 
[8-10]. To date the concensus appears to be that 
chromosome abnormalities do exist in early stages 
of melanocytic neoplasia, and of interest the results 
are surprisingly non-overlapping between abnor- 
malities observed in later stage melanomas. Parmi- 
ter et al. [9] studied a series of melanotic tumors 
including common nevi through metastatic mela- 
nomas and their data supported the view that ter- 
minal region of chromosome 10q (bands q24-q26) 
may harbor one or more genes involved in the early 
stages of melanocytic neoplasia. In contrast, Cow- 
an et al. [8] analyzed cultures from a variety of 
lesions, including congenital and dysplastic nevi, 
primary melanoma and metastatic melanoma with 
results indicating that chromosome 9 (especially 
band region 9pter-p22) may be the site of a gene(s) 
important in the early steps of malignant trans- 
formation of melanocytes. In the study of Cowan 
[8], 22/26 cultures derived from dysplastic nevi had 
totally normal karyotypes, while 100% of cultures 
from primary and metastatic melanomas showed 
chromosome abnormalities. Chromosome 9 as well 
as chromosome 11 were the only two chromosomes 
altered in common between nevi and abnormal 
karyotypes of the malignant melanomas examined. 
In another study by McDonagh et al. [10], a patient 
with an lip-constitutional abnormality was report- 
ed who developed dysplastic nevi at an early age. 
These limited but provocative studies make up a 
selected, but representative base of knowledge re- 
garding cytogenetic analysis from premalignant 
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Fig. 1.Ideograms of human chromosomes most frequently altered in human malignant melanoma. The brackets indicate the most 
frequently altered band regions. 
melanomas. To summarize, results to date suggest 
that patients with a hereditary predisposition for 
melanoma formation may show slightly increased 
levels of spontaneous chromosome abnormalities 
in both peripheral blood lymphocytes and human 
skin fibroblasts. Although, direct cytogenetic ex- 
amination of dysplastic nevi and primary melano- 
mas are still based on very small patient numbers, 
the results clearly suggest that chromosomes 9q 
and 10q may be important sites of chromosome 
change involved early in the genesis of this dis- 
order. The gene(s) which may be disregulated by 
these chromosome abnormalities are not identi- 
fied. However Cowan et al. [8] has suggested that 
the interferon gene cluster which maps to chromo- 
some 9p [11] may be a possible target for the 9q 
chromosome rearrangements. 
Chromosome abnormalities in metastatic 
malignant melanoma 
A number of studies have appeared characterizing 
chromosomal alterations in metastatic melanoma 
[12-24]. Unfortunately, several variables exist in 
regards to the cultured cells so many of these re- 
ports have involved studies of established melan- 
oma cell lines, and even studies of primary out- 
growths have included a number of variables in 
technical procedures (e.g. days in culture, culture 
media, chromosome harvesting techniques, etc.). 
However, despite these variables it is surprising 
that a general pattern of cytogenetic alteration in 
metastatic melanoma is beginning to emerge. First, 
-> 95% of melanomas studied from primary out- 
growths have recognizable chromosomal abnor- 
malities, and the modal chromosome number is 
consistently in the near-triploid range. For exam- 
ple, a recent study from this laboratory [19], the 
modal chromosome number of 27 patients was 61 
chromosomes/cell, with modal numbers ranging 
from - 40-90 chromosomes/cell. 
Within this framework of multiple chromosomal 
rearrangements a number of chromosomes appear 
to be non-randomly involved in structural rear- 
rangements including: 1, 3, 6, 7, 9, 10, 11 and 19. 
Table 1 provides a listing of those recurring chro- 
mosomal alterations currently recognized in malig- 
nant melanoma by the Committee on Structural 
Chromosomal Changes in Neoplasia of the Human 
Gene Mapping (HMG) Workshop [3]. This listing 
recognizes only those abnormalities which have 
been reported by more than one laboratory, and in 
sufficient numbers to meet the criteria for HMG10.5 
[3]. In addition to these recognizable changes mela- 
nomas are often characterized by the presence of 
unidentifiable markers (umars), which are a fea- 
ture of many solid tumors and occur in - 60% of 
metastatic melanomas studied. 
One feature of the chromosome abnormalities of 
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melanoma which is common to other solid tumors 
is the finding that chromosome alterations often 
characterize a chromosome band region, rather 
than a specific unique translocation (e.g. the 
t(9;22) translocation characterizing chronic myelo- 
genous leukemia). Accordingly, as illustrated in 
Table 1, deletions of varying size (or translocations 
with various autosomal partners) may pinpoint a 
'region' most frequently altered, rather than de- 
scribe a single specific chromosome alteration, Fig- 
ure 1 provides pictorial documentation of the band 
regions along chromosomes 1, 3, 6, 7, 9, 10, 11 and 
19 most frequently altered in this disorder. 
Chromosome 1 alterations are without question 
the most frequent site of chromosome change in 
metastatic melanoma with up to 80% of tumors 
displaying numeric or structural alterations (partic- 
ularly flanking the centromere). Nevertheless, 
chromosome 1 is the single most frequently altered 
chromosome in virtually every solid tumor, so the 
biologic significance (and tumor specificity) of 
these changes is currently indeterminate. Of in- 
terest, Nowell and colleagues [18] have described a 
nonreciprocal translocation involving chromo- 
somes 1 and 19 which appears to describe a subset 
of patients with this disease [t(1;19)(q12;p13)]. The 
region involved in chromosome 1 is an area of 
constitutive heterochromatin (thus with little if any 
genic activity) while the region of chromosome 19 
involved in this translocation apparently lies close 
to (but not involving) the chromosomal loci of the 
insulin receptor gene (INSR) [18]. 
Chromosome 6 (both the long and short arm) is 
also very frequently altered in metastatic melan- 
oma, with the most common alteration a simple 
deletion of the long arm (6q-). The region which 
appears to be most consistently lost surrounds 
bands 6q21. In addition to chromosome 6 dele- 
tions, the involvement of chromosome 6 in a series 
of nonreciprocal translocations (primarily with 
chromosome 1 - see Table 1), is also a relatively 
frequent finding in this disorder [20]. This trans- 
location [t(1;6)(q11-12;q15-21)], has been observ- 
ed in both established melanoma cell lines and 
direct cultures, and interestingly the region on 
chromosome 1 involved in this translocation is 
identical to that involved in a translocation with 
chromosome 19 [18]. Although the site of the trans- 
location on chromosome 6 (q12-13) is removed 
from that region most frequently involved in simple 
deletions (6q21), we have suggested that these al- 
terations may in fact may both be related [20]. 
Specifically, the t(1 ;6) is a nonreciprocal transloca- 
tion which in fact leads to the loss of sequences 
distal to 6q11. Thus, simple deletions as well as this 
nonreciprocal translocation both effectively re- 
move sequences on 6q. Southern blotting using a 
panel of polymorphic DNA probes for chromoso- 
Table 1. List of chromosome aberrations in malignant melan- 
oma* 
Region or Type of aberration Status* References 
band 







l q l l - q l 2  t(1;6)(q11-12;q15-21) 1 
6 p l l - q l l  i(6p), translocations II 
6qll-q27 Deletions, I 
translocations 
6q15-q23 t(1;6)(q11-12;q15-21) I 























* From Mitelman I, Kaneko Y, and Trent J. Report on the 
Committee on Structural Chromosome Changes in Neoplasia 
(HGM10.5). Cytogenetic and Cell Genetics, 55:358--386 (1990). 
+ The criteria for each status as per HGM10.5 recommenda- 
tions were: Status I - at least two laboratories have reported the 
abnormality in a total of five cases; Status I I -  at least three cases 
have been reported from two different laboratories. 
mal 6q has recently demonstrated a high percent- 
age of loss of 6q alleles in the tumor cells of patients 
with metastatic melanoma [25]. The possible bi- 
ologic relevance of this loss of chromosome 6q 
sequences in malignant melanoma will be de- 
scribed later in the text. 
Additional chromosomes which have been 
shown to be altered in metastatic melanoma in- 
clude chromosome 7 and 11. Chromosome 7 alter- 
ations most frequently involve the short arm (7p) 
and it is of interest that enhanced expression of the 
epidermal growth factor receptor (EGFR) gene 
(which maps to 7p12) is associated with an in- 
creased number of copies of chromosome 7p in 
early stage melanomas [26]. Chromosome 11 ab- 
normalities are more evenly divided between the 
short arm (particularly the terminal region) and the 
near distal long arm. Mitelman and colleagues [23] 
in a study of six cell lines from three melanoma 
patients have suggested that chromosome l lp  al- 
terations may play a role in melanoma tumorigene- 
sis. The observation of l lp  abnormalities in melan- 
oma may relate somehow to the now well described 
presence of suppressor gene activity at llp13 [27]. 
However, studies of malignant melanoma exam- 
ining the loss of sequences on l lp  using polymor- 
phic probes has provided little evidence supporting 
the frequent loss of DNA within this chromosomal 
region [25, 28, 29]. 
Expression of silver stained nucleolar organizing 
regions (Ag-NORs) in human cancer 
In normal human cells the chromosomal regions 
associated with nucleolar formation (NORs) are 
present on the short arms of the acrocentric (D- 
and G-group of chromosomes) [33]. Simple his- 
tochemical techniques for selectively staining ac- 
tive NORs have been developed and can be used to 
cytologically evaluate the location and number of 
transcriptionally active NORs [34, 35]. Malignant 
tissue (in contrast to normal cells) in vivo often 
display cytologic irregularies in number, size and 
shape of nuclei. Accordingly, studies have ap- 
peared for several years comparing the cytologic 
expression of these ribosomal cistrons in tumor and 
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normal tissue [36]. Studies of AgNORs in benign, 
dysplastic, and malignant melanocytic skin lesions 
have been performed by several laboratories [37- 
40]. The results of Howat et al. [37] illustrate the 
general findings in melanoma for this procedure. 
These investigators applied the AgNOR technique 
to 30 benign nevi, 30 dysplastic nevi and 30 malig- 
nant melanomas. AgNORs in 200 nuclei were 
scored and the means calculated. A significant dif- 
ference was shown to exist between the number of 
AgNORs per nucleus for malignant melanomas 
versus those for benign nevi or dysplastic nevi. 
Additionally, there was no statistically significant 
difference between benign and dysplastic nevi in 
terms of the total number of NORs per cell. The 
problem with this and related studies relates to a 
significant overlap in counts between benign and 
dysplastic tissue, leading to a limiting in the diag- 
nostic potential of this procedure. Thus, the au- 
thors have suggested the AgNOR technique may 
prove to be of value in helping to differentiate 
malignant melanoma from dysplastic nevi, al- 
though it will be unlikely to be of help in separating 
dysplastic from benign nevi. While this method is 
still a research tool, it appears to be gaining some 
support as an adjunct to routine diagnostic histo- 
pathology. 
Relationship of cytogenetic abnormalities and 
clinical outcome in metastatic melanoma 
Although, the value of chromosomal analysis is 
well established in hematopoietic malignancies, 
the relationship between chromosome abnormal- 
ities and clinical outcome in solid tumors has re- 
ceived relatively little study. Recently a study was 
performed in order to determine the distribution of 
clonal chromosomal abnormalities in patients with 
metastatic melanoma, and to correlate these ab- 
normal karyotypes with clinical information [41]. 
These very preliminary analyses revealed that se- 
lected cytogenetic abnormalities were in fact pre- 
dictive of clinical outcome [41]. 
Sixty two patients were entered in this study with 
46 (74%) having sufficient metaphases for study. 
Ninety three percent of these patients had abnor- 
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Fig. 2. Survival curves among patients who had stage III malig- 
nant melanoma with and without abnormalities in chromo- 
somes 7 and 11. Diagonal lines intersecting survival curves de- 
note patients for whom data were censored (used with permis- 
sion). 
mal karyotypes. There was no correlation between 
the presence or absence of normal mitoses and 
death rate (P = 0.89). 
We also examined the representativeness of our 
patient population, and the effect of considering 
particular subsets of patients in our analyses. Addi- 
tionally results were examined for patients whose 
tissue samples were analyzed cytogenetically to de- 
termine whether survival differed from those pa- 
tients for whom cytogenetic analysis could not be 
performed (e.g. no growth, no metaphases, etc.). 
The results of these studies indicated that none of 
the clinical or demographic features examined dif- 
fered significantly [41]. 
When specific chromosome abnormalities were 
examined for their association with clinical out- 
come patients with a structural abnormality of 
chromosome 7 or 11 had a significantly shorter 
survival duration (p < 0.001 and p < 0.02, respec- 
tively) than patients without such chromosome ab- 
normalities (Fig. 2). This was true when survival 
was analyzed from the interval from cytogenetic 
study to death as well as the interval from diagnosis 
to death. Other karyotypic abnormalities exam- 
ined (including those involving chromosomes 1, 3, 
6, 9 and 21) did not correlate significantly with a 
shorter survival period. 
Finally, although the numbers involved in our 
study were clearly insufficient to support a defin- 
itive multivariant analysis, we did perform analyses 
of the relation of structural abnormalities of chro- 
mosome 7 and 11 to survival from biopsy, diagnosis 
and the occurrence of stage 3 disease until death; 
with the variables including age, sex, nodal in- 
volvement, the presence of visceral metastases, 
and stage 3 disease in a proportional-hazards mod- 
el with an underlying Weibull survival distribution. 
The results of the univariant analysis (with regard 
to the relation of these structural abnormalities) 
remained significant when subjected to multivar- 
iant analyses [41]. 
In summary, this aforementioned report on ka- 
ryotypic analyses on patients with metastatic mela- 
noma examined the relation between banded chro- 
mosomal analyses and clinical outcome of disease 
for this important neoplasm. The results indicated 
that shortened survival duration was associated 
with patients with structural abnormalities of chro- 
mosome 7 and 11. Although the abnormalities in- 
volved in these chromosomes were diverse, the 
region of each chromosome was surprisingly con- 
sistent. For example the rearrangements of chro- 
mosome 7 almost exclusively involved the short 
arm (25/27 cases). Similarly there was a clustering 
of chromosomal breakpoints along chromosome 
11, which were about equally divided between the 
short arm (pl l-pl4)  and the long arm (q23-q25). 
The underlying biology related to the observed 
difference in survival is clearly not understood. 
Several cellular oncogenes map to chromosome 7 
and 11 but the influence of these oncogenes (if any) 
on the negative prognostic effects of alterations of 
chromosome 7 or 11 is unclear. 
Finally, because of the large number of compari- 
sons which were necessitated by the study design 
and the number of individual chromosomes exam- 
ined, these results clearly require corroboration. 
Nevertheless, in as much as cytogenetic analysis is 
providing useful information about hematopoietic 
malignancies, it appears likely that analysis of solid 
tumors (such as melanoma) will prove to be of 
similar value. 
Biologic relevance of chromosome abnormalities in 
malignant melanoma 
As mentioned previously molecular examination 
of specific chromosomal abnormalities has pin- 
pointed the site of genes important in the process of 
growth regulation. Because malignant transforma- 
tion is envisioned as a multistep process [42], recent 
studies highlighting the importance of tumor sup- 
pressor genes in the development of several human 
cancers are particularly of interest [43]. The sup- 
porting evidence for tumor suppressor genes is 
Table 2 a. Characteristics of the parental and microcell line 
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based upon a variety of studies including: 1) cytoge- 
netic evidence for deletion of specific chromosomal 
regions, 2) loss of heterozygosity examined by 
RFLP analysis, and 3) study of somatic cell fusion 
experiments. The following section will briefly doc- 
ument an experimental approach using somatic cell 
fusion to assign a potentially important gene for 
malignant melanoma to human chromosome 6. 
As mentioned previously chromosome banding 
analysis of human malignant melanoma has docu- 
mented the nonrandom alteration of chromosome 
6 (particularly the deletion of the long arm). In 
order to determine the relevance of chromosome 6 
abnormalities in melanoma, a normal chromosome 
6 was directly introduced into melanoma cell lines 
[44]. In these studies a human-mouse microcell 
hybrid was generated that contained a single copy 
of chromosome 6 (derived from a normal human 
diploid fibroblast) as its only human component. 
Cell line I.D. Transformed Growth in 
phenotype G418 
(yes/no) ( + / - )  
Chromosome No. tumors/ Soft agar Cell HMB 
six no. injected cloning generation expression 
introduced sites (day 10) efficiency (%) time ( + / - )  
Parental cells 
Parental 
UACC-903 Yes - 
Parental 
UACC-091 Yes - 
Microcell hybrid clones 
UACC-903 
MCH-361C1 No + 
UACC-903 
MCH-361C1R ° Yes - 
UACC-091 
MCH-360CI No + 
UACC-091 
MCH-360C4 No + 
G418 resistant line 
UACC-903 
+ psv2neo Yes + 
20/20 3.6 2,7 + + + A 
12/12 5.4 2.0 + + +  
6 0/12" 0.2 4.6 - -  + 
- 6 /6  N . D .  N . D .  + + +  
6 0/12"* 5.4 2.7 - - +  
6 0/12"* 2.9 6.1 - - +  
2/2 N,D. N.D. N.D. 
Reactivity to HMB-45 was quantitated as uniformly positive [> 80% of all tumor cells postive (+ + +)] to focal reactivity [< 10% of 
tumor cells positive ( - - + ) ]  see Fig. 2. 
"This revertant line was produced by culturing cells from a tumor formed following injection of MCH-361C1. 
* Tumors arose in all animals after growth delay of up to 34 days. In every case examined, loss of the introduced 6 [assessed by 
cytogenetic and RFLP analysis (e.g. Fig. 3B)] occurred coincident with tumor formation. 
** Following 60 days, 40% of animals developed tumors. However, loss of the introduced 6 was again confirmed in all cases by directly 
analyzing tumor tissue by RFLP analysis. 
a Used with permission. 
110 
Fig. 3. Tumor formation 9 weeks following injection of 1 × 10 7 
cells from a malignant melanoma cell line into the right flank of a 
nude (nu/nu) mouse. The identical number of cells from the 
(+ 6) microcell hybrid of this same cell line were injected at the 
same time into the left flank of this animal but were suppressed 
for tumor formation (see ref. 44). 
The retention of chromosome 6 resulted from the 
insertion of the neomycin antibiotic resistance gene 
(psv2neo) into this chromosome 6, and subsequent 
selection of microcell hybrids with medium con- 
taining the neomycin analog G418. This hybrid was 
then used to transfer an entire normal chromosome 
6 into two different human melanoma cell lines via 
microcell transfer. A summary of characteristics of 
the parental and microcell line is presented in Ta- 
ble 2. 
To summarize these results, the in vitro mor- 
phology of one of the two hybrid lines changed 
dramatically in response to the introduction of hu- 
man chromosome 6. Both cell lines showed a dimi- 
nution of melanoma associated antigen expression 
on (+ 6) microcell hybrids, one of the two micro- 
cell hybrids showed a reduction in soft agar clono- 
genicity, and both showed a lengthening of cell 
generation time. With this significant decline in 
melanoma associated antigen expression (together 
with the finding of altered cell morphology and 
diminished agar clonogenecity of (+ 6) microcell 
hybrids), a study was undertaken to determine 
whether the introduction of normal chromosome 6 
would lead to suppression of tumor growth in nude 
mice. 
After injection of cells (5 × 106 - 1 x 107) from 
the parental cell lines and (+ 6) microcell hybrids 
into athymic (nu/nu) mice. Rapid growth occurred 
in 100% of animals from the parental lines within 5 
to 7 days (Table 2, Fig. 3). For both tumor lines 
tested tumor formation was suppressed in animals 
receiving the (+ 6) when compared to the parental 
line. However, in several animals tumors devel- 
oped following initial suppression, and the out- 
growth from these (+ 6) microcell 'revertants' 
were subsequently shown to have lost the intro- 
duced chromosome 6 [44]. As a control for the 
introduction of chromosome 6 into the melanoma 
cell lines the psv2neo gene was inserted by electrop- 
oration into melanoma cell lines and in contrast to 
the introduction of the chromosome 6, the addition 
of the selectable marker did not alter in vitro mor- 
phology or affect tumorigenicity. 
These results have suggested that it may be rea- 
sonable to speculate that genetic information pre- 
sent on chromosome 6 can suppress the malignant 
phenotype of human melanoma cells. Following 
the suggestion of Vogelstein [45], tumor suppres- 
sor genes may have a hierarchial and incremental 
affect on the regulation of cell growth and our 
results may therefore suggest that this gene(s) on 
chromosome 6 may be acting early in the pathway 
of tumor formation. 
Finally, because chromosome 1 is the most fre- 
quently altered chromosome in malignant melan- 
oma, it was of significant interest when Bale et al. 
[46] recently mapped a gene for hereditary cutane- 
ous malignant melanoma-dysplastic nevus to chro- 
mosome lp using molecular genetic techniques and 
multipoint linkage. The authors speculated that 
this discovery could lead to a starting point for 
identifying a gene(s) for this disorder and eventu- 
ally lead to a characterization of its function. How- 
ever, the general significance of this finding is still 
unclear as other groups have failed to demonstrate 
linkage on lp for families with this disorder, and 
further, studies from this same group of loss of 
alleles from the distal part of chromosome 1 appear 
to occur late (rather than early) in melanoma tu- 
mor progression [47]. Nevertheless, this work is 
indeed of interest as a genetic component to the 
hereditary forms of this disease must certainly ex- 
ist, and sequences on lp may to play a role in the 
etiology of this disorder. 
In summary then, on cytogenetic grounds the 
most highlighted karyotypic abnormalities in early 
melanomas involve chromosomes 9 and 10, while 
in metastatic melanoma these chromosomes are 
infrequently altered and instead there is the fre- 
quent involvement particularly of chromosomes 1 
and 6. Further, the only chromosomal loci impli- 
cated in hereditary cutaneous malignant melanoma 
is chromosome lp, but study of melanoma tumors 
appears to indicate that loss of sequences in this 
region are in fact late rather than early events in the 
development of this cancer. The conclusion then to 
be drawn is that much work remains to be done in 
order to understand the molecular basis for this 
important disorder. We should be prepared for 
surprises! 
Conclusions 
This review has provided a brief update on current 
progress in identifying recurring sites of chromo- 
some change in human malignant melanoma. It is 
clear that additional work is required to more com- 
pletely characterize this disorder, nevertheless sev- 
eral inferences can be made. 
- Early stage melanomas and premelanotic le- 
sions are characterized by minimal karyotypic 
alterations and the possible alteration of chrom- 
somes 9p and 10q. 
- Examination of metastatic melanoma impli- 
cates a subset of chromosomes in this disorder 
(particularly 1, 6, 7 and 11). 
- Analysis of AgNORs in melanoma may provide 
a useful adjunct to routine histopathology in 
distinguishing overt melanotic lesions from dys- 
plastic or benign nevi. 
- Clinical correlations of chromosome change in 
malignant melanoma are very preliminary. By 
analogy to work in hematologic malignancies 
these studies may in the future provide impor- 
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tant insights into chromosomal regions whose 
alteration relates to clinical outcome. 
Biologic implications of chromosomal abnor- 
malities in melanoma are also in their infancy. 
However, evidence for suppressor gene activity 
on chromosome 6 has been obtained. 
Continued study of the basic genetics of malig- 
nant melanoma should add significantly to our 
understanding of the causation and progression 
of this disorder. 
Acknowledgements 
Research supported in part by CA29476 and 
CA41183 awarded by the National Cancer Insti- 
tute/National Institutes of Health, Bethesda, MD. 
References 
1. LeeJAH: Etiology, epidemiology, andprognosisofmelan- 
oma and skin neoplasms. Current Opinion in Onc 2: 388- 
393, 1990 
2. Mitelman F: Catalog of chromosome aberrations in cancer, 
4th Edition. New York, Alan R. Liss (in press) 
3. Mitelman F, Kaneko Y, Trent JM: Report of the committee 
on chromosome changes in neoplasia. Cytogenet and Cell 
Genet 55: 358-386, 1990 
4. Jaspers NG,I, Roza-de Jongh EJM, Donselaar IG, Van 
Velzen-Tillemans ,ITM, van Hemel JO, Rumke P, van der 
Kamp AWM: Sister chromatid exchanges, hyperdiploidy 
and chromosomal rearrangements studied in cells from 
melanoma-prone individuals belonging to families with the 
dysplastic nevus syndrome. Cancer Genet Cytogenet 24: 
33-43, 1987 
5. Caporaso N, Greene MH, Tsai S, Pickle LW, Mulvihill J J: 
Cytogenetics in hereditary malignant melanoma and dys- 
plastic nevus syndrome: Is dysplastic nevus syndrome a 
chromosome instability disorder? Cancer Genet Cytogenet 
24: 299-314, 1987 
6. Lynch HT, Fusaro RM, Danes BS, Kimberling WJ, Lynch 
,IF: A review of hereditary malignant melanoma including 
biomarkers in familial atypical multiple mole melanoma 
syndrome. Cancer Genet Cytogenet 8: 325-358, 1983 
7. Sanford KK, Tarone RE, Parshad R, Tucker MA, Greene 
MH, Jones GM: Hypersensitivity to G2 chromatid radiation 
damage in famillial dysplastic naevus syndrome. Lancet ii: 
1111-1116, 1987 
8. Cowan ,IM, Halaban R, Francke U: Cytogenetic anlysis of 
112 
melanocytes from premalignant nevi and melanomas. J 
Natl Cancer Inst 80: 1159-1164, 1988 
9. Parmiter AH, Balaban G, Clark Jr WH, Nowell PC: Pos- 
sible involvement of the chromosome region 10q24-> q26 
in early stages of melanocytic neoplasia. Cancer Genet 
Cytogenet 30: 313-317, 1988 
10. McDonagh AJG, Wright AL, Messenger AG: Dysplastic 
naevi in association with partial deletion of chromosome 11. 
Clinical and Exper Derm 15: 44-45, 1990 
11. Trent J, Olson S, Lawn R: Chromosomal localization of 
human leukocyte, fibroblast and immune interferon genes 
by means of in situ hybridization. PNAS 79: 7809, 1982 
12. Becher R, Gibas Z, Karakousis C, Sandberg AA: Non- 
random chromosome changes in malignant melanoma. 
Cancer Res 43: 5010-5016, 1983 
13. Trent JM, Rosenfeld SB, Meyskens FL: Chromosome 6q 
involvement in human malignant melanoma. Cancer Genet 
Cytogenet 9: 177-180, 1983 
14. Pathak S, Drwinga HL, Hsu TC: Involvement of chromo- 
some 6 rearrangements in human malignant melanoma cell 
lines. Cytogenet Cell Genet 36: 573.579, 1983 
15. Balaban G, Herlyn M, Guerry D, Bartolo R, Koprowski H, 
Clark WH, Nowell PC: Cytogenetics of human malignant 
melanoma and premalignant lesions. Cancer Genet Cyto- 
genet 11: 429--439, 1984 
16. Pedersen MI, Bennett JW, Wang N: Nonrandom chromo- 
some structural aberrations and oncogene loci in human 
malignant melanoma. Cancer Genet Cytogenet 20: 11-27, 
1986 
17. Cowan JM, Halaban R, Lane AT, Francke U: The in- 
volvement of 6p in melanoma. Cancer Genet Cytogenet 20: 
255, 1986 
18. Parmiter AH, Balaban G, Herlyn M, Clark WH, Nowell 
PC: A t(1;19) chromosome translocation in three cases of 
human malignant melanoma. Cancer Res 46: 1526-1529, 
1986 
19. Trent JM, Thompson FH, Meyskens FL: Cytogenetics of 
melanoma. In: T Slaga (ed.) Skin Cancer Biology. Raven 
Press, New York, pp 165-186, 1989 
20. Trent JM, Thompson FH, Meyskens Jr FL: Identification 
of a recurring transloeation site involving chromosome 6 in 
human malignant melanoma. Cancer Res 49: 420-423,1989 
21. Grammatico P, Lo Re ML, Scarpa S, Modesti A, Del Porto 
G: Human malignant melanoma. Significance of chromoso- 
mal abnormalities. Cancer Genet Cytogenet 48: 237-242, 
1990 
22. Limon J, Dal Cin P, Sait SNJ, Karakousis C, Sandberg AA: 
Chromosome changes in metastatic human melanoma. 
Cancer Genet Cytogenet 30: 201-211, 1988 
23. Heim S, Mandahl N, Arheden K, Giovannella BC, Yim 
SO, Stehlin Jr JS, Mitelman F: Multiple karyotypic ab- 
normalities, including structural rearrangements of 11p, in 
cell lines from malignant melanomas. Cancer Genet Cyto- 
genet 35: 5-20, 1988 
24. Kacker RK, Giovanella BC, Pathak S: Consistent karyo- 
typic abnormalities in human malignant melanomas. Anti- 
cancer Res 10: 859-872, 1990 
25. Millikin D, Meese E, Witowski C, Meltzer P, Trent JM: 
Loss of constitutional heterozygosity for loci on chromo- 
some 6q in human malignant melanoma. Cancer Res, in 
press, 1991 
26. Koprowski H, Herlyn M, Balaban G, Parmiter A, Ross A, 
Nowell P: Expression of the receptor for epidermal growth 
factor correlates with increased dosage of chromosome 7 in 
malignant melanoma. Somatic Cell and Mol Genet 11: 297- 
302, 1985 
27. Fearon ER, Vogelstein B, Feinberg AP: Somatic deletion 
and duplication of genes on chromosome 11 in Wilms' tu- 
mours. Nature 309: 176-178, 1984b 
28. Dracopoli NC, Houghton AN, Old LJ: Loss of polymor- 
phic restriction fragments in malignant melanoma: implica- 
tions for tumor heterogeneity. Proe Natl Acad Sci 82: 1470- 
1474, 1985 
29. Nordenskjold M, Werelius B, Ringborg U: Allele losses in 
malignant melanoma reflect random events. Anticancer 
Res 10: 883-886, 1990 
30. Muir PD, Gunz FW: A cytogenetic study of eight human 
melanoma cell cell lines. Pathology 11: 59%606, 1979 
31. Kakati S, Song SY, Sandberg AA: Chromosomes and cau- 
sation of human cancer and leukemia. XXII, Karyotypic 
changes in malignant melanoma. Cancer 40: 1173-1181, 
1977 
32. Atkin NB, Baker MC: A metastatic malignant melanoma 
with 24 chromocomes. Hum Genet 58: 217-219, 1981a 
33. Ferguson-Smith MA: The sites of nucleolus formation in 
human pachytene chromosomes. Cytogenet 3: 124-134, 
1964 
34. Goodpasture C, Bloom SE: Visualization of nucleolar or- 
ganizing regions in mammalian chromosomes using silver 
stain. Chromosoma 53: 3%50, 1975 
35. Howell WM, Denton TE, Diamond JR: Differential stain- 
ing of human acrocentric chromosomes. Experientia 31: 
260-262, 1975 
36. Trent JM, Carlin DA, Davis JR: Expression of silver- 
stained nucleolar organizing regions (Ag-NORs) in human 
cancer. Cytogenet Cell Genet 30: 31-38, 1981 
37. Howat A J, Wright AL, Cotton DWK, Reeve S, Bleehen 
SS: AgNORs in benign, dysplastic, and malignant melan- 
ocytic skin lesions. American Jr Derm 12(2: 156-161, 1990 
38. Crocker J, Skibeck N: Nucleolar organiser region-associ- 
ated proteins in cutaneous melanotic lesions: a quantitative 
study. J Clin Pathol 40: 885-889, 1987 
39. Howat AJ, Girl DD, Cotton DWK, Slater DN: Nucleolar 
organiser regions in Spitz nevi and malignant melanomas. 
Cancer 63: 474-478, 1989 
40. Egan M, Crocker J: Nucleolar organiser regions in cutane- 
ous tumours. J Pathol 154: 247-253, 1988 
41. Trent JM, Meyskens FL, Salmon SI, Ryschon K, Leong 
SPL, Davis JR, McGee DL: Relation of cytogenetic ab- 
normalities and clinical outcome in metastatic melanoma. 
N Engl J Med 322: 1508-1511, 1990 
42. Knudson Jr AG, Hethcote HW, Brown BW: Mutation of 
childhood cancer: A probabilistic model for the incidence 
of retinoblastoma. Proc Natl Acad Sci USA 72: 5116-5120, 
1975 
43. Friend SH, Drya TP, Weinberg RA: Oncogenes and tu- 
mor-suppressing genes. N Engl J Med 318: 618, 1988 
44. Trent JM, Standbridge E J, McBride HL, Meese EU, Casey 
G, Araujo DE, Witkowski CM, Nagle RB: Tumorigenicity 
in human melanoma cell lines controlled by introduction of 
human chromosome 6. Science 247: 568-571, 1990 
45. Vogelstein B, Fearon ER, Kern SE, Hamilton SR, Prei- 
singer AC, Nakamura Y, White R: Allelotype of colorectal 
carcinomas. Science 244: 207-21l, 1989 
46. Bale SJ, Dracopoli NC, Tucker MA, Clark Jr WH, Fraser 
MC, Stanger BZ, Green P, Donis-Keller H, Housman DE, 
113 
Greene MH: Mapping the gene for hereditary cutaneous 
malignant melanoma-dysplastic nevus to chromosome lp. 
N Engl J Med 320: 1367-1372, 1989 
47. Dracopoli NC, Harnett Bale SJ et al.: Loss of alleles from 
distal chromosome lp occurs late in melanoma tumor pro- 
gression. Proc Natl Acad Sci USA 86: 4614-4618, 1989 
Address for offprints: 
Jeffrey M. Trent, 
Emanuel N. Maisel Professor Of Oncology, 
Department of Radiation Oncology and Human Genetics, 
1150 W. Medical Center Drive, 
University of Michigan, 
An Arbor, MI 48109--0668, USA 
